Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Professor calls for better clinical trials of antivirals
Cats suffering from FIV and FeLV require special management and care.

Review looks at antiviral use in retrovirus-infected cats

A leading professor in small animal medicine is calling for better clinical trials of antivirals following publication of a review into their use in retrovirus-infected cats.

Professor Katrin Hartmann, head of the clinic of small animal medicine at the LMU University of Munich, Germany, says that more well-designed clinical trials would improve judgement on treatment efficacy and side effects.

Antiviral chemotherapy is of increasing interest in veterinary medicine, but is still not commonly used.  The review, published in the Journal of Feline Medicine and Surgery, examines current literature on antiviral chemotherapy in retrovirus-infected cats, focusing on drugs that are currently available on the market, and therefore could potentially be used in cats.

Concluding the review, Professor Hartmann writes: 'Unfortunately, the level of efficacy of antiviral chemotherapy is often poor and the duration of treatments used in clinical trials is often inappropriate for infections with such long clinical courses.

'Additionally, the degree of generalisability between experimental infections in cats kept under laboratory conditions and pet cats infected with field strains is unknown.
Therefore, it is very important that more well-designed double-blind, placebo-controlled trials using antivirals in naturally retrovirus-infected cats are undertaken to allow judgement on treatment efficacy and side effects of different antiviral compounds.'

Feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) are among the most common infections affecting cats worldwide, but differ in their potential to cause disease. 
Cats suffering from FIV and FeLV require special management and care and, provided they receive this, can live for many years in good health.

In more severe cases, the advice is to consider incorporating antivirals into the treatment regime. Most antivirals used in cats are licensed for humans and are specifically intended for treatment of human immunodeficiency virus (HIV), based on the rationale that FIV and HIV are closely related.

FeLV is not as closely related to HIV, with the result that the available drugs have mostly been found to be less effective against this retrovirus.

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.